Navigating Medical Device Design Control & Risk Management
Helping you navigate integrated design control and risk management, while providing complete visibility into the entire development process for your medical device.
No doubt: 2018 was an important—and extremely busy—year for FDA. Between engaging with the 21st Century Cures Act and applying critical updates to long-standing programs, the agency has spent the past year working hard to position itself well in the changing landscape of life science industries. While there’s a lot worth discussing about the regulatory year that was 2018, a few important milestones are worth a second look.
The year has drawn to a close, but FDA is not slowing down its pace. December 2018 was a big month for the agency, and there’s a lot to talk about. Here are a few important updates to catch up on as we prepare to move into the new year.
Subscribe to the blog and get this guide for free
For FDA, 2018 was a busy year; the agency began a number of new initiatives, released a plethora of new draft guidance, and took major steps toward greater collaboration among themselves, industry, and other agencies. In the coming year, expect these efforts to keep going and important new initiatives to take flight. In preparing for these regulatory actions, there are four main trends to watch out for.
As the end of 2018 approaches, FDA is busy getting the last of this year’s regulatory activities wrapped up. Here are a few highlights of what they were up to in November.
We’re getting close to the end of the year, and FDA is still working at a solid pace. Here are some of the interesting updates in October 2018 we think are worth checking out.
Next year is shaping up to be big for FDA. Continued initiatives for digital health innovation, industry collaboration, and improving premarket submission processes are going to influence many regulatory actions in 2019. FDA has anticipated this by putting out a list of proposed guidance for development in 2019. The list lacks details on what any new guidance will look like, however. Exploring what’s been proposed, while not definitive, can give your medical device organization a better sense of what FDA might be up to in the coming year.
This past September may have been the busiest month for FDA yet. There’s a lot we could talk about in this edition of the Pulse Check, but there are two areas we’d like to focus on: draft guidance and FDA initiatives.
August has been a busy month for FDA. Here are just a few FDA updates worth keeping an eye on as we move toward the end of summer.